Investigational drug · Phase 2
Reference : ondansetron
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "Reference : ondansetron"
First trial start
2025
Jul 7, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Reference : ondansetron", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nausea and Vomiting Chemotherapy-Induced
- Nausea Post Chemotherapy
Approved drugs for the same conditions: Nausea and vomiting · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Reference : ondansetron" as an intervention, largest first.
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast CancerPivotal-lookingRecruiting
Jiuda ZhaoAcademic, hospital or other
NCT06952920 · 388 participants (planned) · Start Aug 21, 2025 · Primary completion Jun 30, 2028
Drug: standard quadruple antiemetic therapy; standard quadruple antiemetic therapy · For: Standard Quadruple Antiemetic Therapy; Electroacupuncture; Chemotherapy-induced Gastrointestinal Symptom Cluster
Sites: Xining, China
Helsinn Healthcare SAIndustry
NCT06904235 · 95 participants (planned) · Start Jul 7, 2025 · Primary completion Oct 2027
Drug: IV NEPA (fosnetupitant/palonosetron); Reference Treatment: IV ondansetron infusion and 1 more · For: Nausea and Vomiting Chemotherapy-Induced; Nausea Post Chemotherapy
Sites: Athens, Greece; Thessaloniki, Greece; Bialystok, Poland · 20 sites in all
Teva Pharmaceuticals USATeva (TEVA)
NCT00934921 · 24 participants · Start Feb 2003 · Primary completion Feb 2003
Drug: Ondansetron; Zofran® · For: Healthy
Sites: Houston, Texas
Teva Pharmaceuticals USATeva (TEVA)
NCT00934180 · 24 participants · Start Dec 2002 · Primary completion Dec 2002
Drug: Ondansetron; Zofran® · For: Healthy
Sites: Houston, Texas
Aquestive TherapeuticsIndustry
NCT01220167 · 18 participants · Start Aug 2008 · Primary completion Aug 2008
Drug: Ondansetron 8 mg ODFS without water; Ondansetron 8 mg ODFS with water and 1 more · For: Healthy Participants
Nasus PharmaIndustry
NCT07868861 · 12 participants (planned) · Start Sep 15, 2026 · Primary completion Jan 2027
Drug: NS003 Ondansetron HCl microspheres powder for nasal application; Ondansetron Solution for IV infusion 8mg · For: Chemotherapy-Induced Nausea and Vomiting (CINV); Radiotherapy-induced Nausea and Vomiting (RINV); Postoperative Nausea and Vomiting
Sites: Jerusalem, Israel
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.